ArticleFrontiers in pharmacology2026
Naoxintong capsule decreases circulating exosomes of miR-382-5p to protect LPS-induced vascular endothelial cell injury by targeting
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular and cerebrovascular diseases, major health threats in aging populations, involve vascular endothelial injury as a key pathological factor. Circulating exosomes, a type of extracellular vesicles involved in substance transport and signal transduction, serve as regulatory mediators in vascular diseases. Naoxintong Capsule (NXT), a traditional Chinese medicine with 3 decades of clinical application, protects vascular diseases via multifaceted mechanisms, yet its circulating exosome-mediated endothelial protection remains unclear. Methods: Circulating exosomes were isolated from NXT-treated (NXT-Exo) and saline-treated (Ctl-Exo) SD rats. The effect of NXT-Exo and Ctl-Exo on lipopolysaccharide (LPS) induced human microvascular endothelial cells (HMEC-1) injury was studied using molecular biology experiments. RNA-seq and miRNA-omics analysis were performed to elucidate the mechanisms of NXT-Exo. Western blot and enzyme linked immunosorbent assay (ELISA) were used to validate the therapeutic target of NXT-Exo. Results: NXT-Exo attenuated LPS-induced HMEC-1 injury by suppressing apoptosis, inflammation, oxidative stress, and endothelial dysfunction, while Ctl-Exo showed no effect. RNA-seq revealed the TLR4/TRIF/NF-κB signaling pathway might play a crucial role in NXT-Exo's effect. miRNA-omics suggested miR-382-5p as a pivotal mediator, and ELISA confirmed that its downregulation contributes to the protective effect of NXT-Exo. Integrated analysis indicated Stanniocalcin-1 ( Conclusion: Our findings elucidated that NXT protected HMEC-1 from injury and dysfunction by downregulating miR-382-5p in circulating exosomes, potentially via targeting
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.